Cardiology · Heart FailureTrial Updateclinicalmid-term

Tasly Pharma Trials Qishen Yiqi Pills for Chronic Heart Failure

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/20/2026, 6:03:10 AM

Assessment confidence: 64% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial of Qishen Yiqi Dripping Pills by Tasly Pharma represents a significant opportunity to introduce a novel treatment in the chronic heart failure space. Success could not only enhance Tasly's portfolio but also disrupt the current competitive landscape in cardiology. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 8 ranked evidence items (4 high-relevance).

Strategic Assessment

Success in this trial may enhance Tasly's portfolio in cardiology and provide a competitive edge in the treatment of heart failure. The strongest clinical anchor is Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany (ClinicalTrials.gov), sub-indication match (cardiology); sponsor/company relevance (astrazeneca). In cardiology, 2 regulatory and 1 competitive items passed relevance filtering for Tasly Pharmaceutical.

Competitive Pressure

The most relevant competitive pressure comes from Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders (Lilly) — sponsor/company relevance (lilly). This trial could position Tasly's Qishen Yiqi as a novel treatment option in the chronic heart failure market, potentially impacting existing therapies.

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). The trial's outcome will influence future regulatory filings and could set the stage for new treatment guidelines in chronic heart failure management.

Key Risks

Elevated medium regulatory exposure for Tasly Pharmaceutical could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany) could weigh on Tasly Pharmaceutical through efficacy or safety read-through uncertainty if follow-through weakens.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Tasly Pharmaceutical through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

If successful, the trial could lead to market entry for Qishen Yiqi, potentially capturing market share from existing therapies and generating substantial revenue.
Upside for Tasly Pharmaceutical may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Success in this trial may enhance Tasly's portfolio in cardiology and provide a competitive edge in the treatment of heart failure.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any subsequent regulatory filings or partnerships that may arise from the findings.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
Clinical trials for medicines: collection, verification and reporting of safety events
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Clinical trials for medicines: Clinical Trials Regulations transitional arrangements
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology); Sponsor/company relevance (AstraZeneca)
FDA document
View source
Novel Model of Integrated Care of Older Patients With Atrial Fibrillation and Heart Failure in Rural China (MIRACLE-AFHF)
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Advancing Clinical Heart Failure Outcomes Leveraging Defibrillation Lead Implant System for Left Bundle Branch Area Pacing
ClinicalTrials.govmedium relevance
Sub-indication match (cardiology)
FDA document
View source
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Lillymedium relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Otsuka's OPC-167832 Trial for Drug-Susceptible TB Shows Promise Against Standard Regimen
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
University of Missouri-Columbia Launches Naloxone Training Initiative to Combat Opioid Overdoses
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Lactiplantibacillus plantarum (WJL) ameliorates chronic kidney disease by inhibiting fibroblast growth factor 21 adaptive stress response via low protein diet.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Tasly Pharmaceutical

Commercial impact

medium

If successful, the trial could lead to market entry for Qishen Yiqi, potentially capturing market share from existing therapies and generating substantial revenue.

Regulatory impact

medium

The trial's outcome will influence future regulatory filings and could set the stage for new treatment guidelines in chronic heart failure management.

What to watch

Monitor trial results and any subsequent regulatory filings or partnerships that may arise from the findings.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.